Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Enforcement Report - Week of September 26, 2012
  • Print
  • Share
  • E-mail
-
Back to Previous Page

Event Detail

Event ID 63110
Product Type Devices
Status Completed
Recalling Firm RAYSEARCH LABORATORIES AB
City Stockholm
State
Country SE
Voluntary/Mandated Voluntary: Firm Initiated
Recall Initiation Date 2011-05-30
Initial Firm Notification of
Consignee or Public		 Letter
Distribution Pattern Worldwide Distribution - USA including CA, KY, MI, NY, OK, and OR. Internationally to Canada, Belgium, United Kingdom, Australia, France, Germany, and Poland.

Product Detail

Product Description Code Info Classification Reason for Recall Product Quantity Recall Number
The product affected by this notice is sold under the trade name TomoTherapy SharePlan 1.1. To determine if the version you are using is affected, bring up the About box in the SharePlan application and check if the build number reported there is 1.3.1.10. Intended use: t-RayAutoplan is a software that, based on the planned dose distribution from a TomoPlan treatment planning system, generates a family of individually optimized IMRT plans and presents their characteristics to the user in a GUI. Among the generated plans, the user selects and clinically approves a treatment plan and exports it electronically to DICOM, for subsequent treatment of the patient. The intended users of t-RayAutoplan shall be clinically qualified staff, such as medical physicists, medical doctors or dosimetrists SharePlan 1.1, aka t-RayAutoplan version 1.2.1 (build number 1.3.1.10). Class II This field notice concerns two behaviors of the SharePlan (Multiple Fraction Groups and Depth Offset) that may be unexpected and are not clearly described in the user manual. None of these behaviors have caused patient mistreatment or other incidents. However, the described user actions must be adhered to for best agreement between treatment plan evaluation and the clinical outcome of the delivered treatment. 15 units Z-2378-2012
-
-